Insight Resource Library Tap into Gubra’s vast production of publications, webinars, videos and posters to get the latest knowledge and insights within our focus areas: obesity, diabetes, MASH, CKD, IPF and IBD. Filtered (40) Filters Reset all × Adenine diet-induced (ADI) nephropathy mouse × GAN DIO-MASH mouse × Lisinopril × Seladelpar × Search × Resource type Data presentation (1) Poster (25) Publication (12) 3D imaging video (0) Webinar (2) Category × Disease model (223) Cardiovascular disease (11) AngII mouse (2) DIO-ApoE-KO mouse (1) DIO-LDLR-KO mouse (4) DIO-PCK9-AAV mouse (1) Isoprenaline-induced cardiomyopathy (1) Cholangiopathy (1) Bile duct ligation (BDL) mouse (1) Mdr2-KO mouse (1) CNS disease (39) Alzheimer's disease models (9) CNS activation (12) Drug distribution (6) Gene expression (1) Gene therapy (1) Parkinson's disease models (6) Diabetes (33) db/db mouse (17) Non-obese diabetic (NOD) mouse (4) ZDF rat (10) Inflammatory bowel disease (3) Acute DSS-IBD mouse (0) Chronic DSS-IBD mouse (3) Idiopathic pulmonary fibrosis (7) BLEO-IPF mouse (4) Chronic BLEO-IPF mouse (2) HFD-BLEO-IPF mouse (0) Kidney disease (33) Acute kidney injury (4) Bilateral ischemia reperfusion injury (bIRI) mouse (1) Unilateral ischemia reperfusion injury (uIRI) mouse (3) Chronic kidney disease (18) Anti-GBM glomerulonephritis mouse (2) Adenine diet-induced (ADI) nephropathy mouse (5) Polycystic kidney disease (PCK) rat (1) Unilateral ureteral obstruction (UUO) mouse (4) 5/6 nephrectomy (Nx) rat (3) Diabetic kidney disease (17) db/db-UNx mouse (1) ReninAAV UNx db/db mouse (11) ZSF-1 rat (0) Knock-out mouse models (8) Metabolic dysfunction-associated steatohepatitis (76) GAN DIO-MASH mouse (30) GAN DIO-MASH-HCC mouse (8) GAN ob/ob-MASH mouse (5) CDAA-HFD mouse (9) CDAA-HFD rat (10) AMLN DIO-MASH mouse (18) AMLN ob/ob-MASH mouse (13) Obesity (52) Bariatric surgery (10) DIO mouse (23) DIO rat (14) ob/ob mouse (8) Therapeutic Area (242) Alzheimer's disease (13) Alcoholic steatohepatitis (2) Cardiovascular disease (10) Chronic kidney disease (28) Cholangiopathy (1) Diabetes (55) Diabetic cardiomyopathy (2) Diabetic kidney disease (18) Hepatocellular carcinoma (6) Idiopathic pulmonary fibrosis (7) Inflammatory bowel disease (3) Metabolic dysfunction-associated steatohepatitis (84) Obesity (81) Parkinson's disease (8) Target (149) Alpha-synuclein (1) Autotaxin (1) Beta amyloid (4) Acetyl-CoA carboxylase (2) Amylin receptor (4) Angiotensin converting enzyme (ACE) (5) AMPK (1) ASBT (2) CB1 receptor (5) CCK receptor (4) D2 receptor (3) DPP-IV (2) Fatty acid synthase (1) FGF receptor-1 (3) FXR (12) GCC receptor (1) GFRAL (1) Ghrelin receptor (3) GIP receptor (5) GLP-1 receptor (73) GLP-2 receptor (5) Glucagon receptor (5) GPR119 (0) GPR120 (1) G-protein coupled receptor 10 (GPR10) (1) HSD17b13 (1) 5-HT2C receptor (3) IL-1beta receptor (1) Insulin receptor (2) mARC1 (1) MC4 receptor (4) Monoamine transporter (2) Leptin receptor (1) Neuropeptide FF receptor type 2 (1) Neurotensin receptor (1) Nicotinic acetylcholine receptor (1) NPY receptor (2) NMU receptor (2) Paraoxonase-2 (1) PCSK9 (1) PICK1 (1) PPAR (22) PSD-95 (1) Renin–angiotensin system (3) Secretin receptor (1) SGLT-2 (5) TAAR1 (1) TGF-beta (7) TGR5 (2) THR-ß receptor (5) Y2 receptor (3) Compound (146) Aducanumab biosimilar (4) Adeno-associated virus (AAV)-mediated gene therapy (1) A3907 (2) Adrenomedullin (2) Alk5 inhibitor (6) ALT-801 (1) Amylin (3) Amylin receptor agonist (1) BLD-0409 (1) Bromocriptine (2) CHS-131 (1) Captopril (1) Cilofexor (1) Cotadutide (1) DA-1241 (1) Dapagliflozin (2) Dietary intervention (4) Exenatide (9) Elafibranor (9) Empagliflozin (4) Exendin-4 analogues (3) FGF21 (3) Firsocostat (2) GDF15 analogues (1) Ghrelin (1) GIP receptor agonist (1) GIPRA (1) GIP receptor antagonist (1) Glibenclamide (1) GLP-1 (5) GLP-1 receptor agonist (5) GLP-2 (1) Glucagon receptor agonist (1) Glucose-dependent insulinotropic polypeptide (GIP) (1) Guanylin (1) GUB06-046 (1) GUB08-248 (1) GUB09-123 (1) GUB09-145 (2) GUB08251 (1) GUB021794 (1) GUBamy (1) GS-834356 (1) HSD17b13 inhibitor (1) HSG4113 (1) Icosabutate (1) ID166 (0) Insulin (1) INT-767 (4) INT-787 (0) Lanifibranor (9) LEAP-2 (2) Leptin (1) Linagliptin (5) Liraglutide (30) Lisinopril (5) Lorcaserin (3) MEDI0382 (1) mPD95 (1) Neuromedin U (2) Neurotensin (1) Neurturin (1) Nicotine (1) Obeticholic acid (10) Oxyntomodulin (1) PYY3-36 (4) Prolactin-releasing peptide (1) Resmetirom (6) Rimonabant (4) Rosiglitazone (2) S961 (1) Salmon calcitonin (1) SEFA-1024 (1) Seladelpar (2) Semaglutide (31) SER140 (1) Setmelanotide (3) Sibutramine (4) TAAR1 agonists (1) Taspoglutide (1) Teduglutide (2) Tirzepatide (1) TVB-3664 (1) UCCB01-147 (1) Uroguanylin (1) Vutiglabridin (1) Y2 receptor agonist (1) ZP3022 (3) Method/Endpoint (265) 3D imaging (57) Adeno-associated virus (AAV)-mediated gene delivery (14) Atherosclerotic plaques (3) Beta-cell mass (12) Blood pressure (1) Body composition (11) Body weight (123) Blood biochemistry (84) Bariatric surgery (12) Bioinformatics (105) c-Fos activation (19) Clinical trial (2) Conditioned taste aversion test (1) Drug discovery (25) Drug distribution (11) Energy expenditure monitoring (4) Echocardiography (ECG) (3) Flow cytometry (1) Gut biopsy (6) Glomerular filtration rate (GFR) (8) Gastric emptying (3) Gut morphometry (12) Glucose-stimulated insulin secretion (GSIS) (1) Histopathology score (79) Heart morphometry (5) Intraperitoneal glucose tolerance test (IPGTT) (7) Image analysis (150) Immunohistochemistry (IHC) (145) In situ hybridization (ISH) (14) Insulin tolerance test (ITT) (2) Kidney biopsy (2) Kidney morphometry (24) Lung functional test (5) Light sheet fluorescence microscopy (LSFM) (60) Liver biopsy (67) Liver morphometry (65) Lung biochemistry (4) Laser-capture microdissection (LCM) (9) Magnetic resonance imaging (MRI) (2) Microbiomics (5) Micro-computed tomography (micro-CT) (1) Neurobehavior (6) Next-generation sequencing (49) Nephrectomy (14) Oral glucose tolerance test (OGTT) (20) Pancreatectomy (1) Peptide chemistry (14) Pharmacokinetics (9) Proteomics (1) qPCR (1) Real-time food intake/activity analysis (32) Receptor binding (3) Roux-en-Y gastric bypass (RYGB) (8) RNA sequencing (84) Single-cell RNA sequencing (3) Single-nucleus RNA sequencing (6) siRNA (1) StreaMLine (1) Surgery (12) Spirometry (5) Stereology (29) Stereotaxic injection (2) Ultrasound imaging (1) Urine biochemistry (12) Vasculature (2) Vertical sleeve gastrectomy (1) Western Blotting (1) Whole-body plethysmography (4) Whole-brain in situ hybridization (4) Species (219) Hamster (1) Human (29) Mouse (177) Minipig (2) Non-human primate (3) Pig (3) Rat (34) Show (40) Cancel Sort result Default sorting By title: alphabetical By title: reverse By date: oldest first By date: newest first Reset all × Adenine diet-induced (ADI) nephropathy mouse × GAN DIO-MASH mouse × Lisinopril × Seladelpar × 40 resource library items found PosterHepatoprotective effects of semaglutide and tirzepatide therapy in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH PublicationAn unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD) PosterEffect of lisinopril on glomerular and tubular injury in a surgical rat model of progressive chronic kidney disease and kidney failure PosterEffect of lisinopril on glomerular and tubular injury in a surgical rat model of progressive chronic kidney disease and kidney failure PosterReproducible therapeutic effects of lanifibranor and elafibranor in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH PosterAutomated AI-assisted assessment of NAS and fibrosis stage in biopsy-confirmed rodent models of MASH PosterAdditive hepatoprotective effects of semaglutide and resmetirom in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH PosterAdditive hepatoprotective effects of DA-1241, a novel GPR119 agonist, in combination with semaglutide in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH PosterReproducible therapeutic effects of semaglutide in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH PosterNephroprotective effects of dapagliflozin in the adenine-diet induced mouse model of chronic kidney disease PublicationShared and distinct renal transcriptome signatures in 3 standard mouse models of chronic kidney disease PosterReproducible therapeutic effects of resmetirom in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH PublicationDietary intervention reverses molecular markers of hepatocellular senescence in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH PosterClinical translatability of the GAN diet-induced obese and biopsy-confirmed mouse model of MASH PosterShared and distinct renal transcriptome signatures in three standard mouse models of CKD PosterAdenine-induced mouse model of CKD rapidly develops declined kidney function, renal fibrosis, muscle wasting and anemia PosterAI-assisted Gubra Histopathological Objective Scoring Technique (GHOST) for unbiased, fast and accurate assessment of disease severity in rodent models of NASH Data presentationRNA-seq data package PublicationHepatocyte mARC1 promotes fatty liver disease PosterPreclinical efficacy and clinical translatability of elafibranor in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH PosterHepatic immune cell profiling of the GAN diet-induced obese and biopsy-confirmed mouse model of NASH with advanced fibrosis and HCC PosterPreclinical efficacy and clinical translatability of obeticholic acid in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH PublicationHepatoprotective effects of the long-acting FGF21 analogue PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH PosterPreclinical efficacy and clinical translatability of long-acting FGF-21 analogue in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH Load More For further information Contact us Gubra Hørsholm Kongevej 11B 2970 Hørsholm Denmark +45 3152 2650